英語 での Poorly differentiated の使用例とその 日本語 への翻訳
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
-
Programming
The more poorly differentiated tumors are the most aggressive.
Special studies can help in differentiating more poorly differentiated tumors.
G3-4: poorly differentiated or undifferentiated(marked anaplasia, Gleason score of 7- 10).
G3-4：低分化または未分化(高度異型性)(Gleason7-10)。Diffuse adenocarcinomas are undifferentiated or poorly differentiated, and they lack a gland formation.
びまん型腺がんは未分化または低分化型であり、腺形成は認められない。G3- 4= Poorly differentiated or undifferentiated(marked anaplasia)(Gleason score of 7- 10).
G3-4=低分化型または未分化型（高度異型性）（グリソンスコア7～10）。Age≥18 mo GNB nodular neuroblastoma Poorly differentiated or undifferentiated NA Yes H(intermediate).
生後18ヵ月以上GNB、結節型神経芽腫低分化型または未分化型NAありH（中リスク）。Often poorly differentiated tumors do not display such characteristics, making the EM evaluation of little value.
しばしば、低分化腫瘍はそのような特徴を示さず、EM評価もほとんど役に立たない。Activating mutations of AKT1 have been described in 19% of recurrent ormetastatic poorly differentiated papillary thyroid carcinoma.
AKT1活性化変異は、再発または転移した低分化型甲状腺乳頭がんの19％で報告されている。Often poorly differentiated tumors do not display such characteristics, and EM evaluation would be of little value.
しばしば、低分化腫瘍はそのような特徴を示さず、EM評価もほとんど役に立たない。Activating mutations of AKT1 have been described in 19% of recurrent ormetastatic poorly differentiated papillary thyroid carcinoma.
AKT1の活性化変異は、再発したまたは転移性低分化型甲状腺乳頭がんの19％で記述されている。Often poorly differentiated tumors do not display such characteristics, and EM evaluation would be of little value.
低分化腫瘍はこのような特徴をしばしば示さないので、電顕評価はほとんど価値がない。Presence or absence of high-risk features(i.e., positive margins, lymphovascular invasion,perineural invasion, and poorly differentiated histology).
高リスクの特徴の有無（切除断端陽性、リンパ血管性浸潤、神経周囲への浸潤、および低分化組織学など）。High risk: poorly differentiated tumor and/or depth of myometrial invasion is 50% or more and/or tumor is 2 cm or larger.
高リスク：低分化型腫瘍および/または子宮筋層浸潤の深さが50％以上および/または腫瘍径が2cm以上。Among the 110 cases, 87 cases were operated by the end of December 2014:86 cases were histologically confirmed(83 papillary carcinomas and three poorly differentiated carcinomas), and one case was diagnosed as a benign tumor.
症例のうち、110症例のうち、87症例が2014年12月末までに手術され、86症例が組織学的に癌（83症例が乳頭癌、3症例が低分化腺癌）と確定し、1症例は良性腫瘍と診断された。Poorly differentiated and undifferentiated thyroid tumors(anaplastic thyroid cancer) are less common, aggressive, metastasize early, and have a poorer prognosis.
甲状腺低分化腫瘍および未分化腫瘍(未分化甲状腺がん)はまれにみられ、侵攻性で早期に転移するほか、予後不良である。Tumor-like lesions Benign tumors include follicular adenoma. Malignant tumors include papillary carcinoma,follicular carcinoma, poorly differentiated carcinoma, medullary carcinoma, undifferentiated carcinoma, and malignant lymphoma.
腫瘍様病変良性腫瘍は、濾胞腺腫(ろほうせんしゅ)、悪性腫瘍は、乳頭がん、濾胞(ろほう)がん、低分化がん、髄様(ずいよう)がん、未分化がん、悪性リンパ腫が含まれます。Patients with undifferentiated or poorly differentiated histology tumors without MYC/MYCN expression had a 3-year EFS rate of 63.1%± 13.6% and a 3-year OS rate of 83.5%± 9.4%.
MYC/MYCNの発現を伴わない未分化または低分化組織型の腫瘍を有する患児では、3年EFS率は63.1％（±13.6％）および3年OS率は83.5％（±9.4％）であった。Differentiated tumor cells resemble normal cells and tend to grow andspread at a slower rate than undifferentiated or poorly differentiated tumor cells which lack the structure and function of normal cells and grow uncontrollably.
In a randomized trial, 875 men with locally advanced nonmetastatic prostate cancer(T1b-T2 moderately or poorly differentiated tumors; T3 tumors of any grade) were randomly assigned to receive 3 months of an LH-RH agonist plus long-term flutamide(250 mg PO tid) with or without EBRT.
件のランダム化試験において、局所進行非転移性前立腺がん（T1b-T2中分化型または低分化型腫瘍；悪性度を問わないT3腫瘍）の男性875人が、3ヵ月のLH-RHアゴニスト+長期フルタミド（250mg、1日3回経口投与）を受けるEBRT併用群または非併用群にランダムに割り付けられた。In a randomized trial, 875 men with locally advanced nonmetastatic prostate cancer(T1b-T2 moderately or poorly differentiated tumors; T3 tumors of any grade) were randomly assigned to receive 3 months of a luteinizing hormone-releasing hormone agonist plus long-term flutamide(250 mg PO tid) with or without EBRT.
ランダム化試験で、局所進行非転移性前立腺がん（T1b-T2の中分化型または低分化型腫瘍；悪性度を問わないT3腫瘍）の男性875人が、3ヵ月間の黄体形成ホルモン放出ホルモンアゴニスト+長期フルタミド（250mgの1日3回経口投与）を受けるEBRT併用群または非併用群にランダムに割り付けられた。
